Jeito Capital, a global private equity fund, has announced the final closing of its second fund, Jeito II, at a record $1.2 billion. This achievement marks the largest-ever fundraising for a fully independent European fund dedicated to Biopharma. The new fund triples the firm's assets under management to €1.6 billion, cementing its position as a leading investor in the sector.
Strategic Continuity and Expanded Firepower
Jeito II will build upon the successful and differentiated strategy established by its predecessor, Jeito I. The fund will selectively invest in 15 to 20 promising clinical-stage Biopharma companies, primarily located in Europe. Its focus remains on developing breakthrough therapies for severe diseases with significant unmet medical needs.
This substantial fundraising enables Jeito to increase its average investment size in portfolio companies to as much as €150 million. The fund has already begun deploying capital into high-demand therapeutic areas like oncology, neurology, and cardio-metabolic diseases. This financial support is designed to accelerate companies through advanced clinical development and towards commercialization.
Capitalizing on Industry Shifts
The fund's launch is timed strategically as the pharmaceutical industry faces a major patent cliff, potentially reducing revenues by $400 billion by 2033. This dynamic is increasing the reliance of large pharma companies on innovation from smaller Biopharma firms. Jeito is well-positioned to capitalize on the resulting M&A and investment opportunities.
Jeito provides more than just capital, offering portfolio companies guidance from a multidisciplinary team of over 30 experts. This team's experience spans the entire drug value chain, from development and regulatory affairs to commercial operations. Their collective expertise helps advance therapeutic innovations to meet the highest industry standards.
The effectiveness of this approach is demonstrated by Jeito's recent successful exits, including the acquisitions of EyeBio and Hi-Bio. Merck & Co acquired EyeBio for up to $3 billion, while Biogen purchased Hi-Bio for up to $1.8 billion. These transactions highlight the firm's ability to identify and nurture high-value assets.
A Landmark for European Innovation
The record-breaking fundraise for Jeito II sends a powerful message about the strength and potential of the European Biopharma market. It confirms the region's ability to finance and develop the next generation of global leaders in therapeutic innovation. The fund is designed to bridge a critical long-term growth capital gap for scaling companies.
The fund attracted a diversified base of top-tier international investors from Europe, North America, and Asia. Backers include sovereign funds, corporate investors, insurance companies, and pension funds. This widespread support underscores global confidence in Jeito’s patient-driven strategy and the European market's potential.
The successful closing of Jeito II represents a significant milestone, not just for Jeito Capital but for the entire European life sciences ecosystem. By combining substantial financial resources with deep industry expertise, the fund is poised to accelerate medical breakthroughs. This will ultimately help build the next generation of global Biopharma leaders and deliver transformative benefits to patients worldwide.